Executive Decision DeckCompare All →

Head of Business Development, US Specialty

STADA · Remote, United States

Key Criteria

1.Buying-Side Business Development Experience
2.End-to-End Deal Execution Capability
3.US Biotech Network and Relationships
4.Scientific Depth and Technical Fluency
5.Entrepreneurial and Independent Operator

Search Lead: Jackie Wyard-Yates

Click any candidate to view their full assessment

Rama Kataria

Associate Director, Business Development

Alexion Pharmaceuticals·Boston, Massachusetts

PhD biochemist turned BD professional with end-to-end deal execution across nephrology, neurology, and bone health at Alexion. Science-first approach with expanding China biotech network.

▸PhD biochem with postdoc at NIH and Harvard; science-first BD approach

▸End-to-end deal execution from search through CEO presentation at Alexion

▸Direct therapeutic area alignment: nephrology, neurology, bone health

Notice: Not mentionedComp gap

Executive Decision CardView →

Peter Borden

Director of Search & Evaluation Neuroscience

AbbVie·Chicago, IL

PhD biomedical engineer with 3 completed in-licensing deals at AbbVie including $1.2B Aliada neuroscience transaction. Former BCG biopharma strategy consultant with strong scientific credentials.

▸3 completed in-licensing deals including $1.2B Aliada neuroscience transaction

▸PhD biomedical engineering with neuroscience focus from Georgia Tech Emory

▸Global asset evaluation including significant recent China activity

Notice: Not mentionedComp gap

Executive Decision CardView →

Julien Genovino

Associate Director, Global Business Development & Strategy

Otsuka Pharmaceutical Companies·Princeton, New Jersey

Medicinal chemist from Pfizer/Novartis turned BD professional at Otsuka. Closed $600M Phase I immunology acquisition. Exceptional cultural adaptability across 6 countries.

▸Closed $600M Phase I mAb acquisition in immunology at Otsuka

▸Drug discovery background from Pfizer and Novartis across modalities

▸Cross-cultural navigation across Japan, Europe, and US markets

Notice: Not mentionedComp gap

Executive Decision CardView →